The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy
Open accessAbstract
Cytokines are important immunotherapeutics with approved drugs for the treatment of human cancers. However, systemic administration of cytokines often fails to achieve adequate concentrations to immune cells in tumors due to dose-limiting toxicity. Thus, developing localized therapy that directly delivers immune-stimulatory cytokines to tumors may improve the therapeutic efficacy. In this study, we generated novel lipid nanoparticles (LNPs) encapsulated with mRNAs encoding cytokines including IL-12, IL-27 and GM-CSF, and tested their anti-tumor activity. We first synthesized ionizable lipid materials containing di-amino groups with various head groups (DALs). The novel DAL4-LNP effectively delivered different mRNAs in vitro to tumor cells and in vivo to tumors. Intratumoral injection of DAL4-LNP loaded with IL-12 mRNA was most potent in inhibiting B16F10 melanoma tumor growth compared to IL-27 or GM-CSF mRNAs in monotherapy. Furthermore, intratumoral injection of dual DAL4-LNP-IL-12 mRNA and IL-27 mRNA showed a synergistic effect in suppressing tumor growth without causing systematic toxicity. Most importantly, intratumoral delivery of IL-12 and IL-27 mRNAs induced robust infiltration of immune effector cells, including IFN-γ and TNF-α producing NK and CD8+ T cells into tumors. Thus, intratumoral administration of DAL-LNP loaded with IL-12 and IL-27 mRNA provides a new treatment strategy for cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Self-citationDranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Awasthi, A., Carrier, Y., Peron, J. P. S., Bettelli, E., Kamanaka, M., Flavell, R. A., Kuchroo, V. K., Oukka, M., & Weiner, H. L. (2007) · Nature Immunology · doi:10.1038/ni1541 · Cited by 804
Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10
Stumhofer, J. S., Silver, J. S., Laurence, A., Porrett, P. M., Harris, T. H., Turka, L. A., Ernst, M., Saris, C. J. M., O'Shea, J. J., & Hunter, C. A. (2007) · Nature Immunology · doi:10.1038/ni1537 · Cited by 775
Interleukin-12 in anti-tumor immunity and immunotherapy
Colombo, M. P., & Trinchieri, G. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00032-6 · Cited by 685
Interleukin-12: Biological Properties and Clinical Application
Del Vecchio, M., Bajetta, E., Canova, S., Lotze, M. T., Wesa, A., Parmiani, G., & Anichini, A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0776 · Cited by 601
Cytokines in Cancer Immunotherapy
Waldmann, T. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028472 · Cited by 507
Zhang, L., Morgan, R. A., Beane, J. D., Zheng, Z., Dudley, M. E., Kassim, S. H., Nahvi, A. V., Ngo, L. T., Sherry, R. M., Phan, G. Q., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2085 · Cited by 444
Interferons α and β in cancer: therapeutic opportunities from new insights
Borden, E. C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0011-2 · Cited by 423
Hodi, F. S., Lee, S., McDermott, D. F., Rao, U. N., Butterfield, L. H., Tarhini, A. A., Leming, P., Puzanov, I., Shin, D., & Kirkwood, J. M. (2014) · JAMA · doi:10.1001/jama.2014.13943 · Cited by 359
Dranoff, G. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18813.x · Cited by 334
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
Bommareddy, P. K., Patel, A., Hossain, S., & Kaufman, H. L. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0238-9 · Cited by 322
Fitzgerald, D. C., Ciric, B., Touil, T., Harle, H., Grammatikopolou, J., Sarma, J. D., Gran, B., Zhang, G.-X., & Rostami, A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3268 · Cited by 308
An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo
Li, B., Luo, X., Deng, B., Wang, J., McComb, D. W., Shi, Y., Gaensler, K. M. L., Tan, X., Dunn, A. L., Kerlin, B. A., et al. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b03528 · Cited by 261
Self-citationKerkar, S. P., Muranski, P., Kaiser, A., Boni, A., Sanchez-Perez, L., Yu, Z., Palmer, D. C., Reger, R. N., Borman, Z. A., Zhang, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0735 · Cited by 254
Potent Antitumor Activity of Interleukin-27
Hisada, M., Kamiya, S., Fujita, K., Belladonna, M. L., Aoki, T., Koyanagi, Y., Mizuguchi, J., & Yoshimoto, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2084 · Cited by 244
Mansurov, A., Ishihara, J., Hosseinchi, P., Potin, L., Marchell, T. M., Ishihara, A., Williford, J.-M., Alpar, A. T., Raczy, M. M., Gray, L. T., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0549-2 · Cited by 235
Li, Y., Su, Z., Zhao, W., Zhang, X., Momin, N., Zhang, C., Wittrup, K. D., Dong, Y., Irvine, D. J., & Weiss, R. (2020) · Nature Cancer · doi:10.1038/s43018-020-0095-6 · Cited by 233
Self-citationIntratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment
Hewitt, S. L., Bailey, D., Zielinski, J., Apte, A., Musenge, F., Karp, R., Burke, S., Garcon, F., Mishra, A., Gurumurthy, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0472 · Cited by 227
Morales, J. K., Kmieciak, M., Knutson, K. L., Bear, H. D., & Manjili, M. H. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0622-8 · Cited by 214
Momin, N., Mehta, N. K., Bennett, N. R., Ma, L., Palmeri, J. R., Chinn, M. M., Lutz, E. A., Kang, B., Irvine, D. J., Spranger, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2614 · Cited by 204
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
Curran, M. A., Geiger, T. L., Montalvo, W., Kim, M., Reiner, S. L., Al-Shamkhani, A., Sun, J. C., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121190 · Cited by 187
Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing
Zhang, X., Zhao, W., Nguyen, G. N., Zhang, C., Zeng, C., Yan, J., Du, S., Hou, X., Li, W., Jiang, J., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc2315 · Cited by 182
Self-citationSalcedo, R., Stauffer, J. K., Lincoln, E., Back, T. C., Hixon, J. A., Hahn, C., Shafer-Weaver, K., Malyguine, A., Kastelein, R., & Wigginton, J. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7170 · Cited by 161
Cornebise, M., Narayanan, E., Xia, Y., Acosta, E. P., Ci, L., Koch, H., Milton, J., Sabnis, S., Salerno, T., & Benenato, K. E. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202106727 · Cited by 139
Role of interferon-gamma in interleukin 12-induced pathology in mice.
Car, B. D., Eng, V. M., Schnyder, B., LeHir, M., Shakhov, A. N., Woerly, G., Huang, S., Aguet, M., Anderson, T. D., & Ryffel, B. (1995) · Europe PMC (PubMed Central) · Cited by 123
Li, W., Zhang, X., Zhang, C., Yan, J., Hou, X., Du, S., Zeng, C., Zhao, W., Deng, B., McComb, D. W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27434-x · Cited by 115
Self-citationGM-CSF Gene-Modifed Cancer Cell Immunotherapies: Of Mice and Men
Hege, K. M., Jooss, K. U., & Pardoll, D. M. (2006) · International Reviews of Immunology · doi:10.1080/08830180600992498 · Cited by 113
Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells.
Armstrong, C. A., Botella, R., Galloway, T. H., Murray, N., Kramp, J.-P., Song, I. S., & Ansel, J. C. (1996) · PubMed · Cited by 109
Bhatia, S., Longino, N. V., Miller, N. J., Kulikauskas, R. M., Iyer, J. G., Ibrani, D., Blom, A., Byrd, D. R., Parvathaneni, U., Twitty, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0972 · Cited by 102
Liu, Z., Liu, J., Talebian, F., Wu, L., Li, S., & Bai, X. (2012) · European Journal of Immunology · doi:10.1002/eji.201242930 · Cited by 83
Self-citationHu, J., Sun, C., Bernatchez, C., Xia, X., Hwu, P., Dotti, G., & Li, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1365 · Cited by 76
Rosborough, B. R., Castellaneta, A., Natarajan, S., Thomson, A. W., & Turnquist, H. R. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0311119 · Cited by 75
Zhu, S., Lee, D. A., & Li, S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902371 · Cited by 68
Shinozaki, Y., Wang, S., Miyazaki, Y., Miyazaki, K., Yamada, H., Yoshikai, Y., Hara, H., & Yoshida, H. (2008) · International Journal of Cancer · doi:10.1002/ijc.24107 · Cited by 65
IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy
Zhu, J., Liu, J.-Q., Shi, M., Cheng, X., Ding, M., Zhang, J. C., Davis, J. P., Varikuti, S., Satoskar, A. R., Lu, L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98745 · Cited by 65
Self-citationWei, J., Xia, S., Sun, H., Zhang, S., Wang, J., Zhao, H., Wu, X., Chen, X., Hao, J., Zhou, X., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300328 · Cited by 64
Zhang, C., Zhang, X., Zhao, W., Zeng, C., Li, W., Li, B., Luo, X., Li, J., Jiang, J., Deng, B., et al. (2019) · Nano Research · doi:10.1007/s12274-019-2308-9 · Cited by 61
Self-citationPotential clinical application of interleukin‐27 as an antitumor agent
Yoshimoto, T., Chiba, Y., Furusawa, J.-I., Xu, M., Tsunoda, R., Higuchi, K., & Mizoguchi, I. (2015) · Cancer Science · doi:10.1111/cas.12731 · Cited by 57
Effects of local structural transformation of lipid-like compounds on delivery of messenger RNA
Li, B., Luo, X. L., Deng, B., Giancola, J. B., McComb, D. W., Schmittgen, T. D., & Dong, Y. (2016) · Scientific Reports · doi:10.1038/srep22137 · Cited by 47
Self-citationA Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma
Liu, J.-Q., Talebian, F., Wu, L., Li, M., Li, M.-S., Wu, L., Zhu, J., Markowitz, J., Carson, W. E., Basu, S., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600052 · Cited by 45
Self-citationInterleukin-27 Signaling Promotes Immunity against Endogenously Arising Murine Tumors
Natividad, K. D. T., Junankar, S. R., Redzwan, N. M., Nair, R., Wirasinha, R. C., King, C., Brink, R. A., Swarbrick, A., & Batten, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057469 · Cited by 28
Hu, A., Ding, M., Zhu, J., Liu, J.-Q., Pan, X. J., Ghoshal, K., & Bai, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00210 · Cited by 26
Self-citationTumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile
Zhao, Q., Hu, J., Mitra, A., Cutrera, J. J., Zhang, W., Zhang, Z., Yan, J., Xia, X., Mahadeo, K. M., Livingston, J. A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0631-z · Cited by 23
Self-citationLiu, Z., Liu, J.-Q., Shi, Y., Zhu, X., Liu, Z., Li, M.-S., Yu, J., Wu, L., He, Y., Zhang, G., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.989137 · Cited by 21
Self-citationTarhini, A. A., Joshi, I., & Garner, F. (2021) · Immunotherapy · doi:10.2217/imt-2021-0119 · Cited by 18
Is AAV-delivered IL-27 a potential immunotherapeutic for cancer?
Liu, J.-Q., Zhu, J., Hu, A., Zhang, A., Yang, C., Yu, J., Ghoshal, K., Basu, S., & Bai, X. (2020) · PubMed · Cited by 13
Self-citationTalebian, F., Yu, J., Lynch, K., Liu, J.-Q., Carson, W. E., & Bai, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.739816 · Cited by 11
Self-citation
Cited by
Therapeutic cancer vaccines: Advancements, challenges, and prospects
Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597
mRNA-based cancer therapeutics
Liu, C., Shi, Q., Huang, X., Koo, S., Kong, N., & Tao, W. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00586-2 · Cited by 500
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Lu, Q., Kou, D., Lou, S., Ashrafizadeh, M., Aref, A. R., Canadas, I., Tian, Y., Niu, X., Wang, Y., Torabian, P., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01535-8 · Cited by 373
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects
Kon, E., Ad-El, N., Hazan-Halevy, I., Stotsky-Oterin, L., & Peer, D. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00811-9 · Cited by 371
Liu, M., Hu, S., Yan, N., Popowski, K. D., & Cheng, K. (2024) · Nature Nanotechnology · doi:10.1038/s41565-023-01580-3 · Cited by 277
Metadata
- Authors
- Liu, J.-Q., Zhang, C., Zhang, X., Yan, J., Zeng, C., Talebian, F., Lynch, K., Zhao, W., Hou, X., Du, S., Kang, D. D., Deng, B., McComb, D. W., Bai, X.-F., & Dong, Y.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 345
- Pages
- 306-313
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W4220663685
- Cited by
- 262
- References
- 51
- FWCI
- 14.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.